Tag: news

BALA CYNWYD, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Performant Healthcare, Inc. (“Performant Healthcare” or the “Company”) (Nasdaq - PHLT) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Machinify. Under the terms of the transaction, Machinify will acquire all outstanding shares of Performant Healthcare for $7.75 per share in cash.

PITTSBURGH, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Barrett-Jackson Holdings, LLC (“Barrett-Jackson”) recently announced a cybersecurity incident, which impacted the personal information of tens of thousands of individuals. The information potentially impacted in the data breach includes individuals’ names, social security numbers, and driver’s license numbers, financial account information, payment card information, and health insurance information.

BOCA RATON, FL, Aug. 01, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) today announced it will host a live X Spaces conversation on Monday, August 4, 2025, at 1:30 p.m. Eastern Time, titled “July 2025 Business Recap & AMA.”

Direct access to internal architecture information gives AI the vital context it needs to understand, modify, and transform large and complex software applications

PANAMA CITY, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Gate US, the localized platform powered by global crypto leader Gate Group, has officially launched in the United States, now offering spot trading services tailored for U.S. customers. With a focus on security, simplicity, and regulatory compliance, Gate US aims to provide a seamless crypto trading experience supported by world-class infrastructure and trusted industry expertise.

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

Availability of the 2025 Half-year Financial Report